HLB Pharmaceutical Co. Ltd - Asset Resilience Ratio

Latest as of September 2025: 11.61%

HLB Pharmaceutical Co. Ltd (047920) has an Asset Resilience Ratio of 11.61% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of HLB Pharmaceutical Co. Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

₩19.49 Billion
≈ $13.21 Million USD Cash + Short-term Investments

Total Assets

₩167.93 Billion
≈ $113.80 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how HLB Pharmaceutical Co. Ltd's Asset Resilience Ratio has changed over time. See 047920 net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down HLB Pharmaceutical Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of HLB Pharmaceutical Co. Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩19.49 Billion 11.61%
Total Liquid Assets ₩19.49 Billion 11.61%

Asset Resilience Insights

  • Moderate Liquidity: HLB Pharmaceutical Co. Ltd has 11.61% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

HLB Pharmaceutical Co. Ltd Industry Peers by Asset Resilience Ratio

Compare HLB Pharmaceutical Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
Drug Manufacturers - Specialty & Generic 43.05%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
Drug Manufacturers - Specialty & Generic 1.96%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Guobang Pharma Ltd
SHG:605507
Drug Manufacturers - Specialty & Generic 8.47%

Annual Asset Resilience Ratio for HLB Pharmaceutical Co. Ltd (2014–2024)

The table below shows the annual Asset Resilience Ratio data for HLB Pharmaceutical Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 13.92% ₩21.99 Billion
≈ $14.90 Million
₩157.93 Billion
≈ $107.03 Million
-4.38pp
2023-12-31 18.30% ₩25.87 Billion
≈ $17.53 Million
₩141.35 Billion
≈ $95.79 Million
+0.99pp
2022-12-31 17.32% ₩24.62 Billion
≈ $16.69 Million
₩142.18 Billion
≈ $96.35 Million
-2.69pp
2021-12-31 20.01% ₩25.54 Billion
≈ $17.31 Million
₩127.63 Billion
≈ $86.49 Million
-51.12pp
2020-12-31 71.13% ₩79.25 Billion
≈ $53.71 Million
₩111.42 Billion
≈ $75.51 Million
+40.87pp
2019-12-31 30.25% ₩14.04 Billion
≈ $9.51 Million
₩46.39 Billion
≈ $31.44 Million
+21.30pp
2018-12-31 8.95% ₩3.26 Billion
≈ $2.21 Million
₩36.42 Billion
≈ $24.68 Million
-5.79pp
2017-12-31 14.74% ₩5.87 Billion
≈ $3.98 Million
₩39.85 Billion
≈ $27.00 Million
-14.17pp
2016-12-31 28.91% ₩11.92 Billion
≈ $8.08 Million
₩41.24 Billion
≈ $27.95 Million
+27.30pp
2015-12-31 1.61% ₩399.39 Million
≈ $270.66K
₩24.85 Billion
≈ $16.84 Million
-8.95pp
2014-12-31 10.56% ₩2.26 Billion
≈ $1.53 Million
₩21.43 Billion
≈ $14.53 Million
--
pp = percentage points

About HLB Pharmaceutical Co. Ltd

KQ:047920 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$384.53 Million
₩567.42 Billion KRW
Market Cap Rank
#13866 Global
#467 in Korea
Share Price
₩17300.00
Change (1 day)
-2.26%
52-Week Range
₩13040.00 - ₩20900.00
All Time High
₩41100.00
About

HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, anti… Read more